APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
about
Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodiesEvidence for restriction of ancient primate gammaretroviruses by APOBEC3 but not TRIM5alpha proteinsHuman APOBEC1 cytidine deaminase edits HBV DNAReconstitution of an infectious human endogenous retrovirusAPOBEC3 proteins mediate the clearance of foreign DNA from human cellsHIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodiesRestriction of foamy viruses by APOBEC cytidine deaminasesGenetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivoAdaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificitiesPlunder and stowaways: incorporation of cellular proteins by enveloped virusesDifferential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylasesAPOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cellsRole and mechanism of action of the APOBEC3 family of antiretroviral resistance factorsDifferential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activityCrystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfacesHIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factorsRestriction of retroviral replication by APOBEC3G/F and TRIM5alphaAn extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme modelTurning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3)HIV-1 Vif, APOBEC, and intrinsic immunityHuman cytidine deaminase APOBEC3H restricts HIV-1 replicationThe range of human APOBEC3H sensitivity to lentiviral Vif proteinsPolymorphisms and splice variants influence the antiretroviral activity of human APOBEC3HA single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivityCytidine deamination induced HIV-1 drug resistanceIdentification of APOBEC3DE as another antiretroviral factor from the human APOBEC familyAll APOBEC3 family proteins differentially inhibit LINE-1 retrotranspositionInduction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3GHuman immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integrationIntracellular immunity to HIV-1: newly defined retroviral battles inside infected cells.Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversificationDual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retrovirusesMultiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them allThe APOBEC3 family of retroelement restriction factors
P2860
Q21090536-85B07EC9-866E-4589-9C8F-E5708DD3FF19Q21131588-A698CD0F-1B4B-497E-A1C2-0DFE066F2566Q21245048-D3860A1B-7C20-4850-9B0D-DB0C392676D4Q21559512-59218A8A-C785-44EF-A751-8ED7C263A0E5Q24294583-45125298-B0C5-4996-A60C-FFF2A08912A3Q24297395-B8143AEB-AED5-4B4F-AEC7-08A65286A14EQ24299944-1488FCE0-7F7D-4BAC-A7DC-4426477CCEC0Q24305160-94C48D4B-378A-4043-9FB1-4606FE05A682Q24311896-CD3ADD8F-9F9E-4955-82F9-9F53389CB811Q24317568-D85FC55A-9F9D-4D59-BFB9-A07EE661E04AQ24321636-447CC950-DEB8-4468-AC58-3B2C75B66947Q24521469-6A530387-A0F5-4386-BC3E-F60C46BCFDC2Q24524170-87BEBB35-65B6-48B1-9F0D-FB64294787CFQ24529150-D46E50BE-A9CC-4A4B-93AB-35FCEDC310F3Q24530147-0E8535DE-F3D2-4696-B1F9-1FD09DC50D50Q24536003-C94D5816-3E36-4191-9FF5-B4C34411B80FQ24537623-7C8DCD40-2238-4117-8A6E-95681721CE74Q24544264-9BBEDB50-85A8-4606-B248-8E448812E5CFQ24565021-E2431F7A-795C-491A-A15C-B1E4CC23D503Q24599263-3574B469-F991-41C6-BCC6-278CBBDFC201Q24619114-4D63462C-1D3F-432D-AB14-7A59EFBF61D8Q24630459-57FCAE0B-D682-41C9-A09D-3FD15A185FFCQ24642268-BCABF1A3-7D79-4C0A-8E2A-8961CD8F7A63Q24645606-B93F8AF8-9B07-48E8-8200-E6E0D6FA72A4Q24647833-27EADBF0-D97A-4878-92AF-B1A4563A548DQ24653682-4C055E93-8D20-40A8-80FD-632C89B7373DQ24653931-F544DA7B-A1D2-453C-80EE-56D00A3F6484Q24655418-F0C32C87-F08E-4780-8298-BEDBC554BC74Q24656551-13BD3D2F-F773-477E-BCAB-58B428FAC2DFQ24657298-CE20407D-BFCA-4BBF-BDB9-3B69E1E1F4A6Q24670173-AAFF90AC-9AC8-4791-9C89-151A1139CC70Q24675735-2C88E178-22B8-475F-A2D2-A9A22C7CAD5EQ24677778-545B36B1-29F3-4327-B0C7-C53C9BE851D5Q24681427-1390C215-A551-4CF7-A0A1-11CFE561CE3BQ24684279-79ECAB87-ED9A-46EF-9362-434EF357C32DQ24805644-890A7F20-3C79-498A-A815-088AD2B10E13Q24817186-5DFDDFCE-EDD5-4BAF-B71D-E743E01D5093Q25257798-1B99947C-020F-43A1-BA23-5057B7C92F97Q26823568-40D5AB0E-323C-42B7-847A-7D32A9251588Q26862780-124E60AF-FF1E-416A-84D8-66FE38617BFC
P2860
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
@ast
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
@en
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
@nl
type
label
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
@ast
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
@en
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
@nl
prefLabel
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
@ast
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
@en
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
@nl
P2093
P3181
P1433
P1476
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
@en
P2093
April J Schumacher
Mark T Liddament
William L Brown
P304
P3181
P356
10.1016/J.CUB.2004.06.050
P407
P577
2004-08-10T00:00:00Z